Clinical trial of AFP-derived peptide vaccine for hepatocellular carcinoma
Phase 1
- Conditions
- Hepatocellular carcinoma (HCC)
- Registration Number
- JPRN-UMIN000003514
- Lead Sponsor
- Department of Gastroenterology, Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe complications associated with heart, kidney, lung, blood and coagulability 2)Infection of HIV 3)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks 4)Past medical history of immunodeficiency, splenectomy and radiation of spleen 5)medical treatments with steroid or anti-histamine 6)Patients who are during lactation 7)Patients who are during pregnancy and expected pregnancy 8)Past history of organ transplantation 9)Patients who are predicted a difficulty of following clinical course 10)Patients who are judged inappropriate for clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of adverse events and immune responses
- Secondary Outcome Measures
Name Time Method Evaluation of anti-tumor effect and tumor marker